Moreover, recently, new renoprotective agents have been developed for the treatment of DKD, such as sodium glucose cotransporter 2 (SGLT2) inhibitors, selonsertib, finerenone, and atrasentan [37–43]. Here, SLC5A2 is linked to diabetic kidney disease.